Chinese investors wager $105M on an IPO-bound biotech looking to push RNAi as mainstream cancer therapy – Endpoints News

News Snapshot:

Chi­nese in­vestors wa­ger $105M on an IPO-bound biotech look­ing to push RNAi as main­stream can­cer ther­a­py Amber Tong Editor Short­ly af­ter Sir­naomics brought in a $47 mil­lion Se­ries C for its small in­ter­fer­ing RNA pipeline last year, Patrick Lu — the founder, pres­i­dent and CEO — was asked to out­line the sci­en­tif­ic ad­vances that will be nec­es­sary to make bet­ter drugs out of RNA tech. Patrick Lu “The next step in the evo­lu­tion of RNAi as a lead­ing ther­a­peu­tic will be the abil­i­ty to safe­ly tar­get or­gans out­side the liv­er such as lung, brain, etc,” he had of­fered. “This will...